Related Experiment Video
Updated: Oct 12, 2025
03:32
A Pleural Effusion Model in Rats by Intratracheal Instillation of Polyacrylate/Nanosilica
Published on: April 12, 2019
8.1K
Dasatinib-Induced Pleural and Pericardial Effusions.
Yousef M Hailan1, Ahmed Elyas2, Mohammad A Abdulla3
1Internal Medicine, Hamad Medical Corporation, Doha, QAT.
Cureus
|November 26, 2021
Summary
Dasatinib, a tyrosine kinase inhibitor for chronic myeloid leukemia (CML), can cause fluid buildup in the lungs and around the heart. Managing this side effect involves pausing dasatinib and using diuretics and steroids.
Area of Science:
- Oncology
- Pharmacology
Background:
- Chronic myeloid leukemia (CML) is a Philadelphia chromosome-positive myeloproliferative neoplasm.
- Tyrosine kinase inhibitors (TKIs) like dasatinib are standard CML treatment.
- Dasatinib targets the BCR-ABL1 fusion gene central to CML pathogenesis.
Observation:
- A 58-year-old male patient with CML experienced bilateral pleural and pericardial effusions.
- These effusions were classified as grade II severity.
- The adverse events occurred during dasatinib 100 mg once-daily therapy.
Findings:
- Dasatinib administration was associated with the development of significant pleural and pericardial effusions.
- Interruption of dasatinib therapy was a key management strategy.
- Diuretics and steroids were utilized as supportive treatments.
Implications:
- Awareness of dasatinib-induced effusions is crucial for CML patient management.
- These fluid accumulations can negatively impact patient quality of life.
- Managing such side effects may reduce treatment withdrawal rates in CML patients.
Keywords:
chronic myeloid leukemiacmldasatinibpericardial effusionpleural effusiontyrosine kinase inhibitorMore Related Videos
Related Concept Videos
01:19Pericarditis II: Clinical Features and Diagnostic Tests
56
Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...
56
01:25Pleural Effusion I: Introduction
2.3K
Pleural effusion is an abnormal fluid accumulation in the pleural cavity, a narrow space between the lungs and the chest wall. It is not a disease per se but rather a symptom or indication of an underlying disease. In normal circumstances, this space contains a small amount of fluid (5 to 15 mL), a lubricant facilitating the non-frictional movement of the pleural surfaces.
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's...
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's...
2.3K
01:28Pleural Effusion II: Symptoms and Management
321
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
321
01:25Pericarditis IV: Nursing Management
89
Pericarditis, an inflammation of the pericardium, necessitates diligent nursing management to ensure effective patient care and recovery. The initial step in managing pericarditis is a comprehensive patient medical assessment.The patient reports chest pain aggravated by breathing, coughing, and swallowing, which worsens when lying supine. The pain often improves when sitting up and leaning forward. Additional symptoms may include fever, malaise, and, in severe cases, signs of heart failure.
89
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
281
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
281
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
245
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
245